- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory multiple myeloma (MM)
- Meeting Date: July 2026
Belantamab mafodotin – July 2026
- Powder for injection 70 mg (50 mg per ml)
- Powder for injection 100 mg (50 mg per ml)
Public Summary Documents
Last updated
13 November 2026
